From Regulated Tech to Regulated Biotech: How to Move Before the AI Governance Roles Standardise

Two major regulatory developments have reshaped how artificial intelligence will be developed, governed and deployed across European life sciences. Their impact on hiring is only just beginning to emerge.

In the space of twelve months, the European Medicines Agency (EMA) published its draft Annex 22 guidance for AI in GxP environments, while the EU AI Act introduced new legal obligations for high risk AI systems used across healthcare and medical technology. Together, these frameworks have moved AI governance beyond best practice. It is now becoming a regulatory expectation.

For AI engineers, MLOps professionals, data scientists and governance specialists working in regulated technology environments, this shift creates an opportunity that many have not yet considered. Life sciences organisations are looking for professionals who already understand model governance, validation, risk management and technical documentation. These are capabilities that have been developed for years in sectors such as enterprise technology, financial services and software engineering.

What has changed is where those skills are now needed. As life sciences organisations build the governance capability required to meet new regulatory expectations, they are increasingly looking beyond their traditional talent pools. Professionals with strong AI expertise and experience working in regulated environments are becoming some of the most valuable people in the market.

This article explores what is driving that demand, which roles are emerging, and why professionals from outside life sciences may be better positioned for the transition than they realise.

Until recently, organisations developing AI for pharmaceutical manufacturing, medical devices and clinical applications were operating without a dedicated regulatory framework designed specifically for artificial intelligence. Companies were investing in predictive quality, computer vision, clinical decision support and process optimisation, but there was limited guidance on how these systems should be validated, governed and monitored throughout their lifecycle.

That has now changed.

In July 2025, the European Medicines Agency published its draft Annex 22 guidance, introducing the first dedicated GxP framework for AI and machine learning systems. Just over a year later, in August 2026, key provisions of the EU AI Act became applicable for high risk AI systems, with additional requirements for AI-enabled medical devices continuing to come into force through 2027 and 2028.

Together, these developments have established much clearer expectations for how AI systems should be developed, documented and governed within regulated life sciences environments. Rather than treating AI governance as good practice, organisations are increasingly expected to demonstrate that their systems are reliable, transparent and appropriately controlled.

Delivering that level of change will require organisations to build capabilities that many have not previously needed at scale. Professionals who can combine AI expertise with an understanding of regulated environments are therefore becoming increasingly valuable as companies prepare for implementation.

Annex 22 is the European Medicines Agency's proposed framework for AI and machine learning systems used in GxP environments. It sets expectations for areas including model validation, intended use documentation, data quality and traceability, change control, explainability and human oversight. Final publication is expected in 2026, with implementation phased through 2027 and 2028.

In practical terms, organisations will need to demonstrate not only that an AI system performs as intended, but also that its outputs can be understood, monitored and appropriately governed throughout its lifecycle. Dynamic and adaptive models, including generative AI and large language models, remain subject to additional scrutiny in critical GMP applications while regulators continue to evaluate their use.

If you've spent your career building, validating or governing AI systems, much of what Annex 22 expects will feel surprisingly familiar.

Concepts such as model validation, version control, change management, performance monitoring and human oversight have been standard practice in mature AI environments for years. The difference is that, within life sciences, these disciplines are now becoming formal regulatory expectations rather than internal engineering standards. That shift is significant because it changes how organisations think about talent. Instead of looking only for professionals with pharmaceutical experience, many are searching for people who already understand how to develop and manage AI responsibly, then helping them apply those skills within a regulated environment.

For professionals considering a move into life sciences, this creates an interesting dynamic. Many of the technical capabilities employers are now prioritising already exist within mature technology organisations. The opportunity lies in learning how those capabilities are applied within a regulated healthcare environment, where decisions can directly influence product quality, regulatory compliance and, ultimately, patient safety.

That is what makes these roles different. The engineering principles are often familiar. The context in which they are applied is not.

While Annex 22 focuses on how AI should be managed within GxP environments, the EU AI Act introduces a broader legal framework for AI systems used across Europe. For life sciences organisations, it adds another layer of responsibility alongside existing regulations such as MDR, IVDR and GxP.

The practical implication for manufacturers is that AI-enabled medical devices must now satisfy two overlapping frameworks simultaneously: MDR or IVDR requirements covering safety, clinical performance, and post-market clinical follow-up, plus AI Act requirements covering risk management under Article 9, data governance under Article 10, transparency and technical documentation under Article 11, and human oversight under Article 14.

For organisations developing or deploying these technologies, that means demonstrating robust risk management, technical documentation, data governance, human oversight, post market monitoring and appropriate AI literacy across the business. These are no longer optional governance practices. They are becoming regulatory expectations.

For professionals with experience in AI engineering, MLOps or model governance, much of this work will feel familiar. Risk management frameworks, audit trails, documentation standards and performance monitoring are already part of how many mature technology organisations build and maintain AI systems.

The difference is the environment in which those skills are applied. Within life sciences, these processes are scrutinised by regulators and Notified Bodies, with patient safety and product quality at the centre of every decision. As organisations strengthen their AI governance capability, professionals who can bridge technical AI expertise with regulatory thinking are becoming increasingly valuable.

The changes introduced by Annex 22 and the EU AI Act are not creating one new job title. They are creating demand across several specialist disciplines, each requiring a different combination of AI expertise, governance knowledge and regulated environment experience.

The four role categories emerging most consistently across European life sciences in 2026 are:

• AI Validation Specialists: These professionals are responsible for designing and executing validation programmes for AI systems used in GxP environments, including IQ, OQ, and PQ applied to the machine learning lifecycle, validation master plans for AI systems, and ongoing performance qualification. As Annex 22 introduces formal expectations around model validation and lifecycle management, this profile has rapidly moved from a niche capability to one of the most sought-after skill sets across Switzerland, the Netherlands, and Germany.
• AI Governance and Compliance Leads: As organisations prepare for the implementation of Annex 22 and the EU AI Act, demand is increasing for professionals who can build and maintain AI governance frameworks across the business. These roles typically cover AI risk classification, technical documentation under Article 11 of the AI Act, AI literacy programmes under Article 4, post-market monitoring, and governance processes that ensure AI systems remain compliant throughout their lifecycle. Professionals who combine deep technical AI expertise with an understanding of regulatory frameworks are already commanding competitive salaries across several European markets, with the highest typically going to those who can bridge both disciplines.
• MLOps Engineers in Regulated Environments: Many organisations already have data science teams. What they increasingly need are MLOps professionals who understand how to deploy, monitor, and maintain machine learning models within highly regulated environments. That means building infrastructure where every deployment is documented, every model change follows formal change control procedures, and every output can be traced back to validated performance criteria. Within life sciences, however, the real challenge is finding professionals who can apply those skills within GxP environments, where auditability, governance, and validation are as important as technical performance.
• AI Quality Assurance Specialists: Quality Assurance is also evolving alongside AI adoption. Organisations are increasingly looking for QA professionals who understand how AI models behave and how AI oversight can be integrated into existing Quality Management Systems. Responsibilities include reviewing AI validation documentation, developing SOPs for AI assisted decision making and supporting inspection readiness under Annex 22 and the EU AI Act. For many organisations, these professionals will become the link between traditional quality functions and rapidly expanding AI capability.

Across all four role categories, the consistent challenge is not finding people with technical AI skills. It is finding professionals who can combine those skills with an understanding of regulated environments.

Increasingly, organisations are looking for engineers who understand why change control matters, what inspection ready documentation looks like, how CAPAs fit into quality systems and why the human oversight requirements within the EU AI Act are designed to protect both organisations and patients.

For professionals already working in AI, machine learning or MLOps, that combination of skills represents one of the most interesting career opportunities emerging across European life sciences today.

One of the biggest questions professionals ask when considering a move into life sciences is whether the regulatory learning curve will put them at a disadvantage. In reality, many organisations are looking first at the technical capabilities you already have, then assessing how quickly you can apply them within a regulated environment.

Many of the skills now in highest demand already exist within mature AI teams. MLOps infrastructure maps naturally to validated computerised systems. Model governance aligns closely with post market monitoring and lifecycle management. Version control, audit logging and change management are all disciplines that regulated life sciences organisations are now expected to strengthen as AI becomes more widely adopted.

The market reflects that demand. According to PwC's 2025 AI Jobs Barometer, professionals with AI skills earn an average wage premium of 56% compared with similar roles that do not require AI expertise, up from 25% the previous year. Within life sciences, professionals who combine AI capability with an understanding of regulated environments are often able to command an additional premium as organisations compete for this relatively small talent pool.

The knowledge that tends to be missing is rarely technical. It is an understanding of GxP quality systems, regulatory inspections and the documentation standards expected within highly regulated industries. Those are skills that can be learned through experience, mentoring and the right environment.

For professionals with a strong foundation in AI engineering, governance or MLOps, moving into life sciences is often less about starting again and more about applying existing expertise in a sector where it can have a different kind of impact.

The professionals making the transition most effectively in 2026 are doing three things that set them apart from those who are waiting.

First, they are getting specific about the regulatory frameworks before the interview. Reading the EMA's draft Annex 22, which is publicly available at the EMA website, takes ninety minutes. Understanding its six-stage AI lifecycle model, its data governance requirements, and its change control provisions well enough to speak to them in an interview is a meaningful differentiator when most tech candidates cannot. The same applies to the key articles of the EU AI Act: Article 9 (risk management), Article 10 (data governance), Article 11 (technical documentation), and Article 14 (human oversight). These articles are direct analogues of engineering governance practices you already apply.

Second, they are translating their existing work into the language the sector speaks. A model monitoring framework you built at a tech company is a post-market surveillance system in life sciences language. A model card is a technical documentation artefact. A deployment gate process is a change control procedure. These are not loose analogies. They are structural equivalents, and the ability to articulate that equivalence confidently is what makes the difference between a tech candidate who is considered and one who gets shortlisted.

Third, they are moving before the role definition has fully solidified. The organisations building AI validation and governance capability in 2026 are doing so for the first time. The professionals who join at this stage have a disproportionate opportunity to shape what the function looks like, rather than stepping into a pre-defined box. That is a career leverage opportunity that closes as the roles become standardised.

The European life sciences clusters where demand is most acute right now are Basel and the Swiss Mittelland, the Netherlands life sciences corridor between Leiden and Eindhoven, the Munich advanced therapy cluster, and Belgium's pharma belt between Brussels and Ghent.

In each of these geographies, the organisations actively building AI governance capability, large pharma, mid-tier biotech, and CDMOs with digital manufacturing ambitions, are hiring for profiles that did not appear on their headcount plans twelve months ago. AI validation engineers, AI governance leads, and MLOps professionals with regulated environment awareness are being sourced from within the sector, from adjacent regulated industries, and increasingly from big tech, where the supply is deepest and the transferable skills are strongest.

Biotech venture funding grew 70.9% from Q2 to Q3 2025, and 2025 marked the industry's third-busiest year on record for M&A at approximately €206 billion. The programmes being built now and the AI systems being embedded in them are the ones that will require sustained governance capability through the 2027 and 2028 enforcement deadlines and beyond.

The professionals who move now will be building that capability from the ground up, with the regulatory frameworks as their guide and the patient outcomes as their north star. The ones who wait will be competing for roles that have already been defined by someone else.

If you are an AI, MLOps, or data science professional considering a move into life sciences and want to understand which specific organisations and roles in Europe are most aligned to your background right now, we are here to share what we are seeing across active searches.

Get in touch with our team here. [https://www.panda-int.com/meet-the-team/]